Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Sanson

Showing results (191-200 of 290) with videos related to

Pageof 29
Sort By:
Journal of Neuro-Oncology|September 8, 2010
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951Ahmed Idbaih, Cyril Dalmasso, Mathilde Kouwenhoven, et al.
Nature Communications|April 20, 2016
Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomasAurélie Kamoun, Ahmed Idbaih, Caroline Dehais, et al.
Brain Pathology (Zurich, Switzerland)|October 5, 2017
Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular featuresFranck Bielle, Anna-Luisa Di Stefano, David Meyronet, et al.
JCO Precision Oncology|February 1, 2022
Successful Targeting of an ATG7-RAF1 Gene Fusion in Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal DisseminationMehdi Touat, Nadia Younan, Philipp Euskirchen, et al.
Journal of Neuro-Oncology|March 5, 2014
TP53 and p53 statuses and their clinical impact in diffuse low grade gliomasEmeline Gillet, Agusti Alentorn, Brahima Doukouré, et al.
Neuro-Oncology|November 11, 2020
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratificationGiulia Berzero, Anna Luisa Di Stefano, Susanna Ronchi, et al.
Molecular Cancer|September 9, 2010
An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patientsFrançois Ducray, Aurélien de Reyniès, Olivier Chinot, et al.
Journal of Cancer Survivorship : Research and Practice|May 4, 2023
Late-onset vascular complications of radiotherapy for primary brain tumors: a case-control and cross-sectional analysisMaría-José Ibáñez-Juliá, Alberto Picca, Delphine Leclercq, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitorsDiego Prost, Lucia Nichelli, Laura Rozenblum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2008
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie CellulaireCarole Soussain, Khê Hoang-Xuan, Luc Taillandier, et al.
Pageof 29

Showing results (191-200 of 290) with videos related to

Sort By:
Pageof 29
Journal of Neuro-Oncology|September 8, 2010
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951Ahmed Idbaih, Cyril Dalmasso, Mathilde Kouwenhoven, et al.
Nature Communications|April 20, 2016
Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomasAurélie Kamoun, Ahmed Idbaih, Caroline Dehais, et al.
Brain Pathology (Zurich, Switzerland)|October 5, 2017
Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular featuresFranck Bielle, Anna-Luisa Di Stefano, David Meyronet, et al.
JCO Precision Oncology|February 1, 2022
Successful Targeting of an ATG7-RAF1 Gene Fusion in Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal DisseminationMehdi Touat, Nadia Younan, Philipp Euskirchen, et al.
Journal of Neuro-Oncology|March 5, 2014
TP53 and p53 statuses and their clinical impact in diffuse low grade gliomasEmeline Gillet, Agusti Alentorn, Brahima Doukouré, et al.
Neuro-Oncology|November 11, 2020
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratificationGiulia Berzero, Anna Luisa Di Stefano, Susanna Ronchi, et al.
Molecular Cancer|September 9, 2010
An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patientsFrançois Ducray, Aurélien de Reyniès, Olivier Chinot, et al.
Journal of Cancer Survivorship : Research and Practice|May 4, 2023
Late-onset vascular complications of radiotherapy for primary brain tumors: a case-control and cross-sectional analysisMaría-José Ibáñez-Juliá, Alberto Picca, Delphine Leclercq, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitorsDiego Prost, Lucia Nichelli, Laura Rozenblum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2008
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie CellulaireCarole Soussain, Khê Hoang-Xuan, Luc Taillandier, et al.
Pageof 29